71 studies found for:    Alkermes
Show Display Options
Rank Status Study
1 Completed
Has Results
ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults
Condition: Alcoholism
Interventions: Drug: Medisorb naltrexone 380 mg;   Drug: Medisorb naltrexone 190 mg
2 Completed
Has Results
ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)
Condition: Alcohol Dependence
Interventions: Drug: Medisorb naltrexone 190 mg;   Drug: Medisorb naltrexone 380 mg
3 Recruiting Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
Condition: Renal Impairment
Intervention: Drug: ALKS 5461
4 Recruiting A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
Condition: Healthy
Interventions: Drug: Moxifloxacin;   Drug: ALKS 5461;   Drug: Placebo
5 Recruiting A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
Condition: Healthy
Interventions: Drug: ALKS 5461;   Drug: Buprenorphine;   Drug: Placebo
6 Recruiting A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers
Condition: Healthy
Interventions: Drug: Samidorphan IV;   Drug: [14c]-Samidorphan sublingual;   Drug: [14c]-Samidorphan oral
7 Recruiting A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
8 Recruiting A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
Conditions: Schizophrenia;   Alcohol Use Disorder
Interventions: Drug: Samidorphan + olanzapine (ALKS 3831);   Drug: Placebo
9 Recruiting A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
10 Recruiting A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
Condition: Major Depressive Disorder
Interventions: Drug: High Dose ALKS 5461;   Drug: Low Dose ALKS 5461;   Drug: Placebo
11 Completed A Study of ALKS 3831 in Adults With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Samidorphan (Low Dose);   Drug: Samidorphan (Medium Dose);   Drug: Samidorphan (High Dose);   Drug: Placebo;   Drug: Olanzapine
12 Completed A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil or ALKS 9070) in Subjects With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: ALKS 9072;   Drug: Placebo
13 Active, not recruiting An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole Lauroxil
14 Completed A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder
Intervention: Drug: ALKS 5461
15 Completed A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users
Condition: Healthy Volunteers
Interventions: Drug: Samidorphan;   Drug: Placebo;   Drug: Oxycodone
16 Completed A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
Condition: Multiple Sclerosis
Interventions: Drug: Study Drug;   Drug: Active Control;   Drug: Placebo
17 Terminated
Has Results
ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])
Conditions: Alcoholism;   Opiate Dependence
Interventions: Drug: Medisorb naltrexone 380 mg;   Drug: Oral naltrexone to Medisorb naltrexone 380 mg
18 Recruiting Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function
Condition: Hepatic Impairment
Intervention: Drug: ALKS 5461
19 Completed ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
Condition: Opioid-induced Constipation
Interventions: Drug: ALKS 37;   Drug: Placebo
20 Completed ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)
Condition: Opioid-induced Constipation
Interventions: Drug: RDC-1036 (ALKS 37);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years